These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29631441)

  • 21. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
    Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
    Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
    J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study.
    Su CC; Lee YC; Lee PRC
    Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1243-1251. PubMed ID: 33433642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
    Rahmatnejad K; Rapuano CJ; Ichhpujani P; Wizov SS; Moster MR; Hark LA; Katz LJ
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S93-S98. PubMed ID: 28617732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
    Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocular Surface Changes in Primary Open Angle Glaucoma Patients Treated With Topical Antihypertensive Drugs.
    Castro C; Marta A; Marques JH; Ferreira A; José D; Sousa P; Neves I; Menéres MJ; Barbosa I
    J Glaucoma; 2023 Oct; 32(10):e113-e120. PubMed ID: 37523629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye.
    Wong ABC; Wang MTM; Liu K; Prime ZJ; Danesh-Meyer HV; Craig JP
    Ocul Surf; 2018 Jul; 16(3):289-293. PubMed ID: 29510226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
    Sonty S; Mundorf TK; Stewart JA; Stewart WC
    Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers.
    Manni G; Centofanti M; Oddone F; Parravano M; Bucci MG
    Am J Ophthalmol; 2005 Jan; 139(1):72-7. PubMed ID: 15652830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
    Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
    Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of lubricating eyedrops on ocular light scattering as a measure of vision quality in patients with dry eye.
    Diaz-Valle D; Arriola-Villalobos P; García-Vidal SE; Sánchez-Pulgarín M; Borrego Sanz L; Gegúndez-Fernández JA; Benitez-Del-Castillo JM
    J Cataract Refract Surg; 2012 Jul; 38(7):1192-7. PubMed ID: 22727288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study comparing Xalatan
    Diagourtas A; Kagelaris K; Oikonomakis K; Droulias A; Kokolakis N; Papaconstantinou D
    Eur J Ophthalmol; 2018 Jul; 28(4):378-384. PubMed ID: 29952663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy.
    Monaco G; Cacioppo V; Consonni D; Troiano P
    Eur J Ophthalmol; 2011; 21(3):243-50. PubMed ID: 20872359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of ocular surface disease in patients with glaucoma.
    Mathews PM; Ramulu PY; Friedman DS; Utine CA; Akpek EK
    Ophthalmology; 2013 Nov; 120(11):2241-8. PubMed ID: 23714318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Brandt JD; Beiser JA; Gordon MO; Kass MA;
    Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Shimmyo M
    Am J Ophthalmol; 2005 Jun; 139(6):1148; author reply 1148-9. PubMed ID: 15953471
    [No Abstract]   [Full Text] [Related]  

  • 38. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
    Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
    Br J Ophthalmol; 2021 Jan; 105(1):141-148. PubMed ID: 31383648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
    Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
    Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding Ocular Surface Disease in Glaucoma: A Comparative Analysis of Symptoms and Objective Parameters.
    Romano J; Ferreira N; Godinho G; Tomás R; Oliveira N; Sousa JP
    Cureus; 2024 Feb; 16(2):e54070. PubMed ID: 38481920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.